Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2014 | 10 | 1 |
Tytuł artykułu

Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia

Treść / Zawartość
Warianty tytułu
Języki publikacji
Background: Cholinesterase inhibitors and glutamate blockers are commonly used for the treatment of cognitive impairment in Alzheimer’s disease. The aim was to evaluate the effects of rivastigmine and memantine alone or in combination in rats with scopolamine-impaired memory. Method: 5 groups of rats were used: control, scopolamine (model), model with rivastigmine, model with memantine, and model with both drugs. Active avoidance test was performed and the number of conditioned responses, unconditioned responses and intertrial crossing were recorded. Passive avoidance tests step-through with criteria latency of reaction 180 s in the light chamber and step-down with criteria latency of reaction 60 s on the platform were done. Results: Control rats learned the task and kept it on memory tests. Scopolamine treated rats failed to perform it. The rivastigmine, memantine and its combination groups showed increased CRs during learning and memory retention tests. In both passive avoidance tests an increased latency of reaction was observed in the drug treated groups. Conclusion: The combination of both drugs rivastigmine and memantine is more effective than the use of the single drug in cognitive impaired rats. Cholinesterase inhibitors and NMDA blockers may be combined in the treatment of different kind of dementias.
Słowa kluczowe

Opis fizyczny
  • College of William and Mary, Williamsburg,
    Virginia 23187, USA
  • Department of Pharmacology and Clinical
    Pharmacology, Faculty of Medicine, Medical University, Plovdiv
    4002, Bulgaria
  • Department of Pharmacology, Medical Faculty, Medical University,
    15A V. Aprilov str, Plovdiv 4002, Bulgaria
  • ---
  • [1] Wilkinson D. Pharmacotherapy of Alzheimer’s disease. Alzheimer’s disease Psychiatry. 2005;4:43-47
  • [2] Kozhemyakin M, Rajasekaran K, Kapur J. Central cholinesterase inhibition enhances glutamate synaptic transmission. J Neurophysiology. 2010;103:1748-1757
  • [3] Chen Y, Evola M, Young AM. Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine. Psychopharmacology. 2013;225(1):187-199[WoS]
  • [4] Kaufman AM, Milnerwood AJ, Sepers MD, Coquinco A, She K, Wang L. Opposing roles of synaptic and extrasynaptic NMDA receptor signalling in cultured striatal and cortical neurons. J Neurosci. 2012;21(12):3992-4003[Crossref]
  • [5] Tariot PN, Farlow MR, Grossenberg GT. Memantine treatment in patients with moderate to severe Alzheimer’s disease. JAMA. 2004;291:317-324
  • [6] Battaglia F, Wang HY, Ghilardi MF, Gahi E, Quartarone A, Friedman E. Cortical plasticity in Alzheimer’s disease in humans and rodents. Biol Psychiatry. 2007;62:1405-1412[Crossref]
  • [7] Watt AJ, Syӧstrӧm PJ, Häusser M, Nelson SB, Turrigiano GG. A proportional but slower NMDA potentiation follows AMPA potentiation in LTP. Nat Neurosci. 2004;7:518-524[Crossref]
  • [8] Turrigiano GG, Nelson SB. Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci. 2004;5:97-107[Crossref]
  • [9] Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V. et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 2008;7(2):161-172[Crossref][WoS]
  • [10] Watt AJ, van Rossum MC, MacLeod KM, Nelson SB, Turrigiano GG. Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. Neuron. 2000;26:659-670[Crossref]
  • [11] Enz A, Gentsch C. C-administration of memantine has no effect in the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology. 2004;47:408-413
  • [12] Csermansky JG, Martin M, Shah R, Bertchume A, Colvin J. Dong H. Cholinesterase inhibitors ameliorate behavioural deficits induced by MK-801 in mice. Neuropsychopharmacology. 2005;30:2135-2143[Crossref]
  • [13] Markram H, Segal M. Acetylcholine potentiates responses to NMDA receptors in the rat brain hippocampus. Neurosci Letters. 1990;113:62-65
  • [14] Mann EO, Greenfield SA. Novel modulatory mechanisms revealed by sustained application of nicotine in the guinea-pig hippocampus in vitro. J Physiol. 2003;551:539-550
  • [15] Miguel-Hidalgo JJ, Paul IA, Wanzo V, Banerjee PK. Memantine prevents cognitive impairment and reduces Bcl-2 and capsase 8 immunoreactivity in rats injected with amyloid β1-40. Eur J Pharmacol. 2012;692(5):38-45
  • [16] Tucci P, Mhillaj E, Morgese MG, Colaianna M, Zotti M, Schiavone S, et al. Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. Front Behav Neurosci. 2014;19(8):1-11[WoS]
  • [17] Jung JY, Roh M, Ko KK, Jang, HS, Lee SR, Ha JH. Effects of single treatment of anti-dementia drugs on sleep-wake patterns in rats. Korean J Physiol Pharmacol. 2012;16(4):231-236[WoS][Crossref]
  • [18] Anderiambeloson E, Huyard B, Poirand E, Wagner S. Methyllycacoinite- and scopolamine-induced cognitive dysfunction: differential reversal effect by conginition-enhancing drugs. Pharmacol Res Perspect. 2014;2(4):1-8
  • [19] Trebbastoni A, Gilio F, D’Antonio F, Cambieri C, Ceccanti M, de Lena C. Chronic treatment with rivastigmine in patients with Alzheimer’s disease: A study of primary motor cortex excitability tested by 5-Hz repetitive transcranial magnetic stimulation. Clinical Neurophysiology. 2012; 123:902-909
  • [20] Drever BD, Anderson WG, Johnson H, O’Callaghan M, Seo S, Choi DY. 2005. Memantine acts as a cholinergic stimulant in the mouse hippocampus. J Alzheimer’s Dis. 2005;2:319-333
  • [21] Busquet P, Capurro V, Cavalli A, Piomelli D, Reggiani A, Bertolelli R. Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. J Pharm Sci. 2012;20:305-309[Crossref]
  • [22] Wallace TL, Ballard TM, Pouzet B, Rieder WJ, Wettstein JG. Drug targets for cognitive enhacement in neuropsychiatric disorders. Pharmacol Biochem Behav. 2011;99:130-145
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.